首页> 外文OA文献 >Response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR , ALK and KRAS mutation status

【2h】

Response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR , ALK and KRAS mutation status

机译：根据EGFR，ALK和KRAS突变状态从最近诊断的非小细胞肺癌接受放射治疗的基线脑转移患者的反应率

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Oscar Arrieta; Laura‐Alejandra Ramírez‐Tirado; Enrique Caballé‐Perez; Alberto Mejia‐Perez; Zyanya Lucia Zatarain‐Barrón; Andrés F. Cardona; Francisco Lozano‐Ruíz; Manuel Segura‐González; Graciela Cruz‐Rico; Federico Maldonado; Rafael Rosell;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR , ALK and KRAS mutation status [J] . Oscar Arrieta, Laura‐Alejandra Ramírez‐Tirado, Enrique Caballé‐Perez, Thoracic cancer. . 2020,第4期

机译：根据EGFR，ALK和KRAS突变状态从最近诊断的非小细胞肺癌接受放射治疗的基线脑转移患者的反应率
2. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases [J] . Kimberley S. Mak, Justin F. Gainor, Andrzej Niemierko, Neuro-Oncology . 2015,第2期

机译：EGFR，ALK或KRAS靶向治疗和基因改变对非小细胞肺癌脑转移放疗患者生存的意义
3. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)Sabine Schmid, Oliver Gautschi, Sacha Rothschild, ^z>Michael Mark, Patrizia Froesch, Dirk Klingbiel, Hermann Reichegger, Wolfram Jochum, Joachim Diebold, Martin Fruh, [J] . Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第4期

机译：ALK阳性非小细胞肺癌（NSCLC）患者的临床结果（NSCLC）患者DE Novo EGFR或KRAS共突变接受酪氨酸激酶抑制剂（TKIS）Sabine Schmid，Oliver Gautschi，Saha Rothschild，^ Z> Michael Mark，Patrizia Frosech， Dirk Klingbiel，Hermann Reichegger，Wolfram Jochum，Joachim Diebold，Martin Fruh，
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR ALK and KRAS mutation status [O] . Oscar Arrieta, Laura‐Alejandra Ramírez‐Tirado, Enrique Caballé‐Perez, 2020

机译：根据EGFRALK和KRAS突变状态最近被诊断为非小细胞肺癌的放疗后基线脑转移患者的缓解率
7. Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs) [O] . Sabine Schmid, Oliver Gautschi, Sacha Rothschild, 2017

机译：alk阳性非小细胞肺癌（NSCLC）患者的临床结果，涉及酪氨酸激酶抑制剂（TKIS）的德诺伊州EGFR或KRAS共突变

Response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR , ALK and KRAS mutation status

著录项

引文网络

相似文献

相关主题

期刊订阅